Figure 4
High IGSF6 expression is benefit from immunotherapy. (A) Radiological and pathological response to FOLFOX plus sintilimab in a pMMR patient with stage T3N0M0 (Case 1) and FOLFOX plus sintilimab in a pMMR patient with stage T3N1M0 (Case 2). Radiographic imaging shows the tumor in rectum (I, a) at initial diagnoses. A notable tumor regression could be seen in primary tumor from Case 1 (II). But there was no response in Case 2 after ICI (b). Primary tumor was observed using colonoscopy (III, c) at initial diagnosis and after ICI treatment (IV, d). H&E staining shows primary tumor at initial diagnosis and pathological response after ICI treatment. Fibrosis and an infiltration with viable density of many lymphocytes (arrowheads) can be found, which cannot be found in case 2. IHC staining showed CD4+ T cells, CD8+ T cells, CD68+ macrophage cells and IGSF6 expression with pretreatment tumor samples and posttreatment tumor tissues. (B) Quantification of the score for CD4+ T cells, CD8+ T cells, CD68+ macrophage cells and IGSF6 staining before treatment in CRC tissue from immunotherapy sensitive versus immunotherapy resistance assessed by IHC assay, n = 6. (C,D) OS curve of patients with high IGSF6 and low IGSF6 group in TCGA database (C) and GSE39582 database (D).
